TVRD
Tvardi Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.62 / 10
Netural
Fund-flow sentiment is positive with a 7.25/10 score, reflecting solid capital inflow across block, small, medium, and large orders despite a negative overall trend. Analyst coverage is moderate (3 analysts) with ratings split: Strong Buy (33.3%), Buy (33.3%), Neutral (33.3%). Historical win rates for these predictions are low (0.0%), and the market-weighted rating is 0.0%, indicating limited confidence. The combination suggests that while money is entering, analyst conviction is weak, and price action has been falling (-14.29%).
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
33%
Buy
33%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-10-13
InstitutionBarclays
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for TVRD?
- TVRD holds a Bearish analyst rating, with 33% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.62/10 (Netural).
